Successful translational R&D needs equity ownership

12/6/2012 | Forbes

Early-stage translational research and development projects in life sciences are likely to fall flat in the absence of equity ownership in startup companies, writes Atlas Venture partner Bruce Booth. Equity ownership "rewards the successful entrepreneur and binds them together with the academic founders, key advisors, and the broader shareholders," he writes. Equity rewards risk-takers and entrepreneurs, thus encouraging investment, he writes.

View Full Article in:

Forbes

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI